🇺🇸 ROVALCYTE in United States

720 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Neutropenia — 126 reports (17.5%)
  2. Agranulocytosis — 116 reports (16.11%)
  3. Leukopenia — 94 reports (13.06%)
  4. Anaemia — 69 reports (9.58%)
  5. Pancytopenia — 63 reports (8.75%)
  6. Diarrhoea — 58 reports (8.06%)
  7. Acute Kidney Injury — 57 reports (7.92%)
  8. Cytomegalovirus Infection — 49 reports (6.81%)
  9. Drug Interaction — 44 reports (6.11%)
  10. Thrombocytopenia — 44 reports (6.11%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is ROVALCYTE approved in United States?

ROVALCYTE does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for ROVALCYTE in United States?

University Hospital, Rouen is the originator. The local marketing authorisation holder may differ — check the official source linked above.